X4 is nearing approval of its lead candidate for WHIM syndrome and aims for label expansion to a much larger market of chronic neutropenias. Despite very small WHIM target population, orphan ...

“The U.S. approval of our first biosimilar is a very significant milestone for Amneal. Biosimilars represent the next wave of providing access to affordable medicines in the U.S.” Chirag and Chintu ...

Approval was based on data demonstrating similarity between the 2 the biosimilar and reference product, Neupogen. Releuko, a leukocyte growth factor, is approved to: Decrease the incidence of ...

Releuko ® (filgrastim-ayow), a biosimilar to Neupogen ® (filgrastim), is now available in the US for the treatment of neutropenia. Releuko, a leukocyte growth factor, is indicated to: Decrease the ...